Skip to content

SARS-CoV-2 (COVID-19) Detection Using the Breath Analizer TeraSystem

SARS-CoV-2 (COVID-19) Detection Using the Breath Analizer TeraSystem

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04497610
Enrollment
0
Registered
2020-08-04
Start date
2022-11-30
Completion date
2022-11-30
Last updated
2022-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID19

Keywords

SARS-CoV-2, coronavirus testing

Brief summary

The purpose of the study is to verify the sensibility and accuracy of a rapid detection test for SARS-CoV-2 in breath samples analyzed by the breath detector analyzer TeraSystem, comparing with PCR tests.

Detailed description

BioSafety Technologies has developed a rapid detection test to clear people of COVID-19. A person can undergo an easy non-invasive test, to determine if they are: COVID-19 Clear (Negative) or Infected (Positive). The user-friendly process does not involve medically trained personnel. The study will compare TeraSystem test results against PCR test results. Persons participating will be persons having a PCR test as part of the Health System and consenting to participate.

Interventions

DIAGNOSTIC_TESTBreath sample

Patient will blow into a tube 5 times.

Sponsors

Instituto Costarricense de Investigaciones Clínicas ICIC
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
7 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Older than 7 years odf age Able to provide informed consent Able to take the breath test

Exclusion criteria

Younger than 7 years of age Unable to provide informed consent Unable to take the breath test

Design outcomes

Primary

MeasureTime frameDescription
Presence of disease1 minuteEstablished diagnosis

Countries

Costa Rica

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026